Literature DB >> 2002248

Classification and diagnosis of mastocytosis: current status.

D D Metcalfe1.   

Abstract

Mastocytosis is a disease characterized by an abnormal increase in mast cells. Manifestations of the disease are provoked in large part by the resultant increase in mast cell-derived mediators, which have a variety of local and systemic effects. Mastocytosis is variable in respect to the organ systems involved, clinical manifestations, and association with hematologic diseases. This has suggested the need for an improved classification scheme to allow assessment of prognosis and therapy. The heterogeneity of the disease patterns in mastocytosis strongly suggests that more than one biologic lesion may occur in the developmental sequence that leads to placement of mature mast cells in tissues.

Entities:  

Mesh:

Year:  1991        PMID: 2002248

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  38 in total

1.  Increased angiogenesis in the bone marrow of patients with systemic mastocytosis.

Authors:  Friedrich Wimazal; John-Hendrik Jordan; Wolfgang R Sperr; Andreas Chott; Sana Dabbass; Klaus Lechner; Hans P Horny; Peter Valent
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

2.  ["Smoldering systemic mastocytosis. "Successful therapy with cladribine].

Authors:  V Schleyer; S Meyer; M Landthaler; R-M Szeimies
Journal:  Hautarzt       Date:  2004-07       Impact factor: 0.751

3.  Mast cell activation syndrome: Proposed diagnostic criteria.

Authors:  Cem Akin; Peter Valent; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2010-10-28       Impact factor: 10.793

Review 4.  Mast cells and mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Blood       Date:  2008-08-15       Impact factor: 22.113

5.  High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.

Authors:  Robert Fritsche-Polanz; Marika Fritz; Andrea Huber; Karl Sotlar; Wolfgang R Sperr; Christine Mannhalter; Manuela Födinger; Peter Valent
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

6.  Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Authors:  Barbara Peter; Karoline V Gleixner; Sabine Cerny-Reiterer; Harald Herrmann; Viviane Winter; Emir Hadzijusufovic; Veronika Ferenc; Karina Schuch; Irina Mirkina; Hans-Peter Horny; Winfried F Pickl; Leonhard Müllauer; Michael Willmann; Peter Valent
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

7.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

Authors:  B J Longley; D D Metcalfe; M Tharp; X Wang; L Tyrrell; S Z Lu; D Heitjan; Y Ma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

Authors:  H Nagata; A S Worobec; C K Oh; B A Chowdhury; S Tannenbaum; Y Suzuki; D D Metcalfe
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

9.  Phenotypic characterization of skin lesions in urticaria pigmentosa and mastocytomas.

Authors:  N Haas; K Hamann; J Grabbe; B Algermissen; B M Czarnetzki
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

Review 10.  Gastrointestinal manifestations of systemic mastocytosis.

Authors:  Jason K Lee; Scott J Whittaker; Robert A Enns; Peter Zetler
Journal:  World J Gastroenterol       Date:  2008-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.